Patience David 4

What Happened

• Patience David, Chief Financial Officer of TriSalus Life Sciences, acquired 3,657 shares on 2026-02-23. The shares were purchased at $4.10 per share for a total transaction value of $14,994. The Form 4 reports this as a purchase (transaction code P), so this was an insider buy rather than a sale.

Key Details

• Transaction date: 2026-02-23
• Transaction type: Open market/private purchase (Form 4 code P)
• Price per share: $4.10
• Shares acquired: 3,657
• Total value: $14,994
• Shares owned after transaction: Not specified on the filing
• Footnotes / plans referenced: No 10b5-1 plan, tax-withholding, or other footnotes disclosed on this report
• Filing timeliness: Filing date matches the report date (2026-02-23); no late-filing indication in the filing

Context

• Insider purchases are often watched by investors as a sign of confidence, but small-dollar buys (this one is about $15k) are relatively modest and should be considered alongside other factors. This report is a straightforward purchase — not an option exercise, gift, or sell — and the filing does not provide additional explanation for the purchase.